Latest Market Leadership News

AVITA Medical reveals a bold expansion plan targeting a $3.5 billion U.S. acute wound care market by 2025, driven by a multi-product portfolio and sustained revenue growth.

REA Group has posted robust growth in its Q3 results, driven by strong buyer demand and strategic product enhancements across its digital real estate platforms.

Generation Development Group (GDG) has forged a strategic alliance with BlackRock, combining local market leadership with global investment expertise to develop innovative retirement income solutions for Australian retirees.

Althea Group Holdings has agreed to sell its pharmaceutical assets to Tasmanian Botanics, enabling a strategic pivot towards the booming North American THC-infused beverage market.

National Australia Bank (NAB) reported steady cash earnings and improved return on equity in the first half of 2025, underpinned by strong capital ratios and a clear strategic focus on business banking, deposits, and proprietary home lending.

BrainChip Holdings Ltd’s 2025 AGM reveals a strengthened product roadmap, breakthrough Edge AI technology advances, and a surge in commercial partnerships, positioning the company for accelerated growth.

XPON Technologies reported a modest 1% quarter-on-quarter revenue increase to $2.09 million in Q3 FY25, driven by a strong 87% recurring revenue base and a 75% gross margin. The company extended its convertible note maturity and is focused on recalibrating sales and accelerating AI innovation.

Atomos Limited announces a key leadership transition with COO Peter Barber appointed CEO, succeeding co-founder Jeromy Young who will remain on the board as a Non-Executive Director.

First Graphene Limited reported a successful A$2.4 million capital raise alongside promising progress in its PureGRAPH-CEM product trials in the UK and South Africa, while securing key patents and expanding distribution across Asia and South America.

Holista Colltech has closed its ASIC penalty chapter with a $900K final payment, raised $1.53 million through convertible notes, and reported a 10.9% year-on-year sales increase driven by its Dietary Supplements division.

ReNerve Limited reported a 39% sales increase in Q3 FY25 alongside compelling clinical validation of its NervAlign® Nerve Cuff and strategic international partnerships, positioning the company for broader market penetration.

Echo IQ Limited marked a pivotal quarter with FDA clearance for EchoSolv AS, strategic US partnerships, and a clear path toward reimbursement and broader commercialisation.